A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...

Khaberni - Early cancer detection technologies are undergoing a radical transformation with the emergence of multicancer blood tests (MCED), which rely on the analysis of free DNA ...

The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time GRAIL Announces U.S. Sales Force Expansion Based on ...

A recent study suggests that a freely available AI tool could help predict dangerous complications after stem cell transplants.

A new light-based imaging approach has produced an unprecedented chemical map of the Alzheimer’s brain. Rice University researchers have produced what they describe as the first full, label-free ...

By Priyanjana Pramanik, MSc. Large international cohort data suggest plant-forward eating patterns and certain micronutrients ...

GRAIL reported that 2025 total revenue rose 17% year on year to $147.2 million, driven by a 26% increase in U.S. Galleri sales to $136.8 million, while net loss narrowed sharply to $408.4 million and ...

Nikki Romanik and Ashish K Jha propose a new surveillance system to detect and attribute emerging biological threats to enable a rapid public health response Recent advances in bioengineering ...

MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year ...